Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 11/20 | 0.54 |
| ▸ | CDK2 | P24941 | 11/20 | 0.54 |
| ▸ | CDK5 | Q00535 | 10/20 | 0.54 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20877569 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL24246502 | 0.93 | SMN1; SMN2 (0.61) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| Trifluoroacetic Acid SCHEMBL29380781 | 0.92 | CCNE1 (0.50) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL20883052 | 0.90 | SMN1; SMN2 (0.66) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL20883077 | 0.90 | SMN1; SMN2 (0.66) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL22523005 | 0.89 | CCNE1 (0.54) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL22523043 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL22522948 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| SCHEMBL20883064 | 0.82 | CCNE1 (0.55) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 | |
| Trifluoroacetic Acid SCHEMBL20877541 | 0.82 | CCNE1 (0.50) | SMN1; SMN2CCNE1CDK2CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692028-B1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS INC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2022-06-16 | — | — | US | disclosed |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | FORMA THERAPEUTICS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. | 2020-10-08 | — | — | US | disclosed |
| EP-3692028-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | Forma Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019071073-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | FORMA THERAPEUTICS, INC. (US) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185806-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | SMN1; SMN2 88/4885CCNE1 3461/4885CDK2 1919/4885 |
| US-11247987-B2 | Inhibiting ubiquitin specific peptidase 30 | USP30, UCHL1, UCHL3 | SMN1; SMN2 181/4885CCNE1 2017/4885CDK2 1051/4885 |
| US-20200317658-A1 | INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 30 | USP30, UCHL1, UCHL3 | SMN1; SMN2 88/4885CCNE1 3461/4885CDK2 1919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.